ABSTRACT
In order to analyze the occlusion of TMD patient, 73 casts and post eroanterior cephalometric X-rays of patients showing TMD symptoms at first interview were measured and compared that of 30 non-patients. Horizontal overjet, vertical overbite, openbite, crossbite, depth of curve of Spee, midline deviation, facial asymmetry, attrition, and TPI were measured and processed statistically. The results could be summarized as follows, 1. TMD group showed the highest prevalence in twenties, teens, and before 9 years old group in order, and more prevalent in female than male. 2. There were no statistically significance between two groups of overjet and overbite measurements, but showed significance of 6 classification of anterior tooth relationship between two groups TMD groups. 3. TMD group had more anterior openbite than normal group but there were no statistically significance between two groups. 4. Anterior crossbite was more prevalent in normal group but posterior crossbite was more prevalent in TMD group. 5. TMD group showed deeper curve of Spee and there were statistically significance between two groups. 6. TMD group had more attrition than normal group and there were statistically significance beween two groups. 7. TMD group showed more facial asymmetry than normal group. 8. TPI did not showed statistical significance between two groups. According to the above results, TMD group showed severe and complex mode of malocclusion and this should be carefully regarded when treatment planning and during the treatment of malocclusion.
Subject(s)
Adolescent , Child , Female , Humans , Male , Classification , Dentition , Facial Asymmetry , Malocclusion , Open Bite , Overbite , Prevalence , ToothABSTRACT
BACKGROUND: The cell-mediated immunity is needed for eradicating the tubercle bacilli. Prosta- glandin(PG), especially PG E2, is involved in cellular immunosuppression. It is known that the PG E2 is suppressed by indo- methacin. For using indomethacin as a immunomodulator of intractable pulmonary tuberculosis(Tbc) patients, we measured the tuberculin skin test(TST) and the plasma PG E2 levels. METHOD: The forty-eight inpatients with sputum positive acid-fast stain bacilli were classified into 6 groups according to antiTbc chemotherapy history(new and intractable cases), plain chest roetgenogram(minimal and far advanced cases), and TST reaction(nagative and positive cases). Except for one group(n=2; new, minimal, and negative cases of TST reaction) of the 6 groups, all subjects(n=46) were measured for the plasma PG E2 levels with radioimmunoassay. RESULTS: 1) There was no significiant difference in the plasma PG E2 levels among A group(far advanced and positive TST reaction cases, n=10, 11.22 +/-2.86 pg/ml), B group(minimal and negative TST reaction cases, n=9, 11.35 +/-2.20) and C group(far advanced and positive TST reaction cases, n=7, 11.11+/-2.30) in the new cases(p >0.05). 2) There was no significiant difference in the plasma PG E2 levels between positive(n=10, 9.25 +/- 2.21) and negative(n=10, 8.25 +/- 1.13) groups by TST in the intractable cases(p>0.05). 3) Comparing the plasma PG E2 levels between new(n=26, 11.35 +/-2.41) and intractable(n=20, 8.75 1.78) groups, the intractable group had significi- antly lower plasma PG E2 levels(p0.05). 5) There was no significiant difference in the plasma PG E2 levels between male(n=32, 10.07 +/- 2.44) and female(n=14, 10.56 +/-2.70)(p >0.05). 6) There was no significiant difference in the plasma PG E2 levels among 2nd(n=5, 10.21 +/-2.86), 3rd(n=9, 9.97+/-2.47), 4th(n=13, 11.35+/-2.33) and 5th(n=19, 9.57+/-2.48) decades(p>0.05). 7) There was no significiant correlation between the induration sizes of the TST and the plasma PG E2 levels(r=0.054, p>0.05). CONCLUSION: From the above results, the plasma PG E2 levels of intract- able group are not higher as the authors had expected. There was no significiant difference in the plasma PG E2 levels by the lesion sizes of plain chest roetgengram and the induration sizes of TST, so more study will be needed to use the indomethacin as a immunomodulator for intractable pulmonary thberculosis patients.